Biochip, and method for the selective identification of chlamydia trachomatis infections
AssigneeMikrogen GmbH
InventorsUlrike Simnacher, Vera Forsbach-Birk, Andreas Essig, Klaus-Ingmar Pfrepper
Life of this patent
Estimating the term…
Loading patent…
AssigneeMikrogen GmbH
InventorsUlrike Simnacher, Vera Forsbach-Birk, Andreas Essig, Klaus-Ingmar Pfrepper
Estimating the term…
The present invention relates to a method for the selective identification of Chlamydia trachomatis infections wherein the antigens CT017, CT098, CT318-L1 P, CT431-TARP, CT603-TSAP, and CT664 are used for the specific identification of Chlamydia trachomatis antibodies in samples from mammals. The method according to the invention facilitates the selective identification method of identification of Chlamydia trachomatis infections, in which no false positive results are generated by other Chlamydia species such as, for example, Chlamydia pneumoniae. The invention further relates to a biochip which has the aforementioned Chlamydia trachomatis-specific antigens for the identification of antibodies. The biochip with antigens according to the invention is suitable for multiparameter identification methods in particular.
A method for the selective detection of Chlamydia trachomatis infections, said method comprising the step of detecting antibodies in a sample using least two antigens selected from the group consisting of CT017, CT098, CT318-L1P, CT431, CT456-TARP, CT603-TSAP and CT664, and from fragments and partial sequences of the above antigens, the fragments having at least 15 successive amino acids of the antigens, and from antigens that are substantially identical to the aforementioned antigens.
A test kit for the selective detection of Chlamydia trachomatis infections, said kit containing at least two antigens selected from the group consisting of:
A biochip for the detection of Chlamydia trachomatis-specific antibodies, said biochip having at least two antigens selected from the group consisting of:
A method for the differential diagnosis of a chlamydial infection, said method utilizing an antigen selected from the group consisting of CT017, CT098, CT318-L1P, CT431, CT456-TARP, CT603-TSAP and CT664 and partial sequences of these antigens, which have at least 20 successive amino acids of the sequence with SEQ ID NO:
Dependencies are inferred from the claim text.